Scientists race to develop next generation of COVID vaccines
Go Deeper.
Create an account or log in to save stories.
Like this?
Thanks for liking this story! We have added it to a list of your favorite stories.
The three COVID-19 vaccines available in the United States are safe, effective and were made in record time.
But they aren't ideal.
An ideal vaccine — besides being safe and effective — would have a few other desirable characteristics, says Deborah Fuller, a vaccine researcher at the University of Washington.
They would include being "administered in a single shot, be room temperature stable, work in all demographics, and even pushed beyond that, ideally be self-administered," she says.
Turn Up Your Support
MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all.
Now, researchers are racing to develop the next generation of COVID-19 vaccines, utilizing a variety of innovative technologies to produce more convenient and more potent options. Some of the new vaccines are already being tested in volunteers and could even be available for distribution in the next year or so.
Scientists are exploring one set of changes that should be popular with people who don't like needles.
"We wanted to develop a platform technology where we could easily give a vaccine and obviously the easiest format to give would be a tablet," says Sean Tucker, chief scientific officer at Vaxart.
The COVID vaccine Vaxart is developing is similar to Johnson & Johnson's in that it uses a harmless virus to deliver instructions to cells to make proteins that will prompt an immune response to the coronavirus.
But instead of putting the delivery virus in a liquid, Vaxart freeze-dries it, turning into a powder that can be formulated into a pill that can be stored at room temperature.
Another vaccine that could be self-administered is a nasal spray vaccine. Frances Lund, chair of the microbiology department at the University of Alabama at Birmingham, is working on that kind of vaccine with the biotech company Altimmune. She says when you give people a vaccine by injection, the protection is systemic — that is, it works throughout the body.
By contrast, an intranasal vaccine induces two kinds of immunity, Lund says. You still get the systemic protection, she says, "but you will also get immunity directly at the site where you put that vaccine."
That makes it harder for the coronavirus to sneak in through the nose.
Researchers also are testing whether the tablet and nasal spray could be a single dose.
In addition to new ways to administer COVID vaccines, there are also more potent versions on the horizon — meaning they will get the same or better immune response from a lowered dose.
One way of doing that is to modify something called the spike protein, which prompts the immune response to the coronavirus.
Molecular biologist Jason McLellan at the University of Texas at Austin found that a synthetic form of the spike made a more potent vaccine if you added two amino acids called proline. Now he's made a version with six prolines.
It's a "much-improved spike" compared to the two-proline version, and more stable, too, McLellan says.
Another possible improvement is the way the spike protein is packaged for delivery in a vaccine.
Jeff Baxter, CEO of VBI Vaccines, says his company is making synthetic nanoparticles festooned with spike proteins that better mimic the coronavirus.
"The size of these particles is perfect for fooling the immune system," he says.
The immune system of the person receiving the vaccine will react as if it's encountered the real virus, when it's actually a harmless mimic. That's the whole trick behind vaccines — getting the body's immune system ready if the real thing comes along.
Another approach to making something that looks like a virus, but really isn't, is to grow the virus-like particle in plants. Turns out if you give plants the genetic instructions for making coronavirus proteins, they also can make synthetic particles that resemble the virus — which can then be used in a vaccine.
Dr. Brian Ward is medical officer at Medicago, one of the companies trying the plant-based approach. He says it's an unusual and positive thing to have so many different kinds of vaccines against a single disease.
"That gives us an opportunity to do some things that we've really never done before," Ward says.
He says there's some evidence that starting with one kind of vaccine, and then switching to another, may give better immunity than a single vaccine could do on its own.
In the end, among the most important qualities a new vaccine should have are that it should be able to be made and modified quickly in response to variants, as well as distributed quickly.
Dr. Nicole Lurie is strategic adviser at CEPI, the Coalition for Strategic Preparedness and Innovations. She says getting the current crop of vaccines out in about a year was a huge achievement.
"But a year is way too long," Lurie says. "So the aspiration right now is really to think about, 'OK, what do we need to do to do this in 100 days?'"
Lurie says it's virtually certain the world will face new and dangerous microbes that will need vaccines that are "safe and effective, fast, easy to use, preferably a single dose."
That way, she says, "when the next one comes, we're much closer to the starting gate than we even were for this one."
Copyright 2021 NPR. To see more, visit https://www.npr.org.